[{"address1": "321 Harrison Avenue", "address2": "Suite 900", "city": "Boston", "state": "MA", "zip": "02118", "country": "United States", "phone": "617 949 2643", "website": "https://www.monterosatx.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Monte Rosa Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. The company develops MRT-2359, an orally bioavailable molecular glue degrader targeting the translation termination factor protein GSPT1 for the treatment of MYC-driven tumors; MRT-6160 for the treatment of systemic and central nervous system autoimmune diseases; and MRT-8102 for the treatment of IL-1?/NLRP3 driven inflammatory diseases. It also develops CDK2 to treat ovarian, uterine, and breast cancers. The company was incorporated in 2019 and is headquartered in Boston, Massachusetts.", "fullTimeEmployees": 129, "companyOfficers": [{"maxAge": 1, "name": "Dr. Markus  Warmuth M.D.", "age": 52, "title": "President, CEO & Director", "yearBorn": 1971, "fiscalYear": 2023, "totalPay": 924600, "exercisedValue": 0, "unexercisedValue": 2041632}, {"maxAge": 1, "name": "Dr. Filip  Janku M.D., Ph.D.", "age": 49, "title": "Chief Medical Officer", "yearBorn": 1974, "fiscalYear": 2023, "totalPay": 713200, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Jennifer  Champoux", "title": "Chief Operating Officer", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. John C. Castle Ph.D.", "age": 52, "title": "Chief Data & Information Officer", "yearBorn": 1971, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Sharon  Townson Ph.D.", "age": 48, "title": "Chief Scientific Officer", "yearBorn": 1975, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Andrew  Funderburk", "title": "Senior VP and Head of IR & Strategic Finance", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Philip  Nickson J.D., Ph.D.", "age": 44, "title": "Chief Business & Legal Officer", "yearBorn": 1979, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Magnus  Walter DPHIL", "title": "Senior Vice President of Drug Discovery", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Edmund  Dunn", "age": 57, "title": "Vice President & Corporate Controller", "yearBorn": 1966, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 8, "boardRisk": 7, "compensationRisk": 8, "shareHolderRightsRisk": 8, "overallRisk": 8, "governanceEpochDate": 1727740800, "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 4, "previousClose": 4.87, "open": 4.93, "dayLow": 4.86, "dayHigh": 5.11, "regularMarketPreviousClose": 4.87, "regularMarketOpen": 4.93, "regularMarketDayLow": 4.86, "regularMarketDayHigh": 5.11, "beta": 1.424, "forwardPE": -2.614973, "volume": 89931, "regularMarketVolume": 89931, "averageVolume": 349351, "averageVolume10days": 156680, "averageDailyVolume10Day": 156680, "marketCap": 300112992, "fiftyTwoWeekLow": 2.765, "fiftyTwoWeekHigh": 8.84, "priceToSalesTrailing12Months": 52.111996, "fiftyDayAverage": 5.617, "twoHundredDayAverage": 5.2966, "currency": "USD", "enterpriseValue": 82238120, "floatShares": 36596514, "sharesOutstanding": 61372800, "sharesShort": 5232009, "sharesShortPriorMonth": 3273659, "sharesShortPreviousMonthDate": 1726185600, "dateShortInterest": 1728950400, "sharesPercentSharesOut": 0.0853, "heldPercentInsiders": 0.0070599997, "heldPercentInstitutions": 0.86748004, "shortRatio": 8.36, "shortPercentOfFloat": 0.1559, "impliedSharesOutstanding": 61372800, "bookValue": 3.664, "priceToBook": 1.3346069, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1719705600, "netIncomeToCommon": -130414000, "trailingEps": -2.22, "forwardEps": -1.87, "enterpriseToRevenue": 14.28, "enterpriseToEbitda": -0.624, "52WeekChange": 0.5774194, "SandP52WeekChange": 0.39389753, "exchange": "NMS", "quoteType": "EQUITY", "symbol": "GLUE", "underlyingSymbol": "GLUE", "shortName": "Monte Rosa Therapeutics, Inc.", "longName": "Monte Rosa Therapeutics, Inc.", "firstTradeDateEpochUtc": 1624541400, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "e1526429-092c-3bce-8f14-de475e92b666", "messageBoardId": "finmb_690261281", "gmtOffSetMilliseconds": -14400000, "currentPrice": 4.89, "targetHighPrice": 20.0, "targetLowPrice": 11.0, "targetMeanPrice": 15.83, "targetMedianPrice": 16.0, "recommendationMean": 1.6, "recommendationKey": "buy", "numberOfAnalystOpinions": 6, "totalCash": 262204992, "totalCashPerShare": 4.273, "ebitda": -131783000, "totalDebt": 44356000, "quickRatio": 6.424, "currentRatio": 6.562, "totalRevenue": 5759000, "debtToEquity": 19.743, "revenuePerShare": 0.097, "returnOnAssets": -0.27986, "returnOnEquity": -0.59506, "freeCashflow": -57035500, "operatingCashflow": -61004000, "grossMargins": 1.0, "operatingMargins": -6.9525, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-10-28"}]